tradingkey.logo

Bio Rad Laboratories Inc

BIO
300.930USD
+1.070+0.36%
收盘 12/19, 16:00美东报价延迟15分钟
8.12B总市值
亏损市盈率 TTM

Bio Rad Laboratories Inc

300.930
+1.070+0.36%

关于 Bio Rad Laboratories Inc 公司

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Bio Rad Laboratories Inc简介

公司代码BIO
公司名称Bio Rad Laboratories Inc
上市日期Mar 17, 1980
CEOSchwartz (Norman D)
员工数量7700
证券类型Ordinary Share
年结日Mar 17
公司地址1000 Alfred Nobel Dr
城市HERCULES
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编94547
电话15107247000
网址https://www.bio-rad.com/
公司代码BIO
上市日期Mar 17, 1980
CEOSchwartz (Norman D)

Bio Rad Laboratories Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Norman D. Schwartz
Mr. Norman D. Schwartz
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.39M
+214.86%
Ms. Colleen Corey
Ms. Colleen Corey
Executive Vice President, Global Human Resources
Executive Vice President, Global Human Resources
19.55K
+5.80%
Mr. Sedat Evran
Mr. Sedat Evran
Executive Vice President - Global Supply Chain
Executive Vice President - Global Supply Chain
2.02K
+53.88%
Mr. Jonathan P. (Jon) Divincenzo
Mr. Jonathan P. (Jon) Divincenzo
President, Chief Operating Officer
President, Chief Operating Officer
919.00
--
Ms. Eva Anette Engelhardt
Ms. Eva Anette Engelhardt
Executive Vice President, President of Clinical Diagnostics Group
Executive Vice President, President of Clinical Diagnostics Group
896.00
+470.70%
Mr. Gregory K. (Greg) Hinckley, CPA
Mr. Gregory K. (Greg) Hinckley, CPA
Lead Independent Director
Lead Independent Director
808.00
+61.60%
Ms. Courtney C Enloe
Ms. Courtney C Enloe
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
612.00
+414.29%
Mr. Arnold A. Pinkston
Mr. Arnold A. Pinkston
Independent Director
Independent Director
308.00
--
Mr. Jeffrey L. (Jeff) Edwards
Mr. Jeffrey L. (Jeff) Edwards
Independent Director
Independent Director
308.00
--
Ms. Melinda Litherland
Ms. Melinda Litherland
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Norman D. Schwartz
Mr. Norman D. Schwartz
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.39M
+214.86%
Ms. Colleen Corey
Ms. Colleen Corey
Executive Vice President, Global Human Resources
Executive Vice President, Global Human Resources
19.55K
+5.80%
Mr. Sedat Evran
Mr. Sedat Evran
Executive Vice President - Global Supply Chain
Executive Vice President - Global Supply Chain
2.02K
+53.88%
Mr. Jonathan P. (Jon) Divincenzo
Mr. Jonathan P. (Jon) Divincenzo
President, Chief Operating Officer
President, Chief Operating Officer
919.00
--
Ms. Eva Anette Engelhardt
Ms. Eva Anette Engelhardt
Executive Vice President, President of Clinical Diagnostics Group
Executive Vice President, President of Clinical Diagnostics Group
896.00
+470.70%
Mr. Gregory K. (Greg) Hinckley, CPA
Mr. Gregory K. (Greg) Hinckley, CPA
Lead Independent Director
Lead Independent Director
808.00
+61.60%

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
United States
266.90M
40.96%
Europe
217.20M
33.33%
APAC
126.40M
19.40%
Other
41.10M
6.31%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月30日 周日
更新时间: 11月30日 周日
持股股东
股东类型
持股股东
持股股东
占比
First Eagle Investment Management, L.L.C.
11.50%
The Vanguard Group, Inc.
8.17%
Alice N. Schwartz Revocable Trust
8.13%
BlackRock Institutional Trust Company, N.A.
6.77%
Schwartz (Norman D)
6.36%
其他
59.06%
持股股东
持股股东
占比
First Eagle Investment Management, L.L.C.
11.50%
The Vanguard Group, Inc.
8.17%
Alice N. Schwartz Revocable Trust
8.13%
BlackRock Institutional Trust Company, N.A.
6.77%
Schwartz (Norman D)
6.36%
其他
59.06%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
43.38%
Investment Advisor
40.44%
Individual Investor
8.25%
Corporation
8.13%
Hedge Fund
5.13%
Research Firm
1.16%
Bank and Trust
1.15%
Pension Fund
1.14%
Sovereign Wealth Fund
0.63%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
1040
20.58M
101.60%
-3.97K
2025Q3
1095
20.58M
103.17%
+603.60K
2025Q2
1114
19.81M
108.02%
-855.27K
2025Q1
1146
19.96M
99.31%
-2.83M
2024Q4
1140
19.39M
101.48%
-657.49K
2024Q3
1121
20.03M
101.42%
-386.71K
2024Q2
1139
20.32M
91.46%
+1.29M
2024Q1
1154
19.07M
91.02%
-2.25M
2023Q4
1187
19.09M
89.28%
-259.69K
2023Q3
1170
19.31M
88.28%
-552.69K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
First Eagle Investment Management, L.L.C.
2.52M
11.45%
+223.05K
+9.72%
Jun 30, 2025
The Vanguard Group, Inc.
1.84M
8.38%
-59.61K
-3.13%
Jun 30, 2025
Alice N. Schwartz Revocable Trust
1.78M
8.1%
--
--
May 01, 2025
BlackRock Institutional Trust Company, N.A.
1.54M
7.02%
-98.58K
-6.00%
Jun 30, 2025
Schwartz (Norman D)
447.98K
2.04%
+5.20K
+1.17%
Sep 06, 2025
Dimensional Fund Advisors, L.P.
999.57K
4.55%
+122.53K
+13.97%
Jun 30, 2025
Veritas Asset Management LLP
863.14K
3.92%
-49.98K
-5.47%
Jun 30, 2025
Ariel Investments, LLC
818.62K
3.72%
+93.96K
+12.97%
Jun 30, 2025
EARNEST Partners, LLC
605.89K
2.75%
+6.26K
+1.04%
Jun 30, 2025
State Street Investment Management (US)
584.37K
2.66%
-110.15K
-15.86%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Parnassus Value Select ETF
3.94%
First Trust Indxx Medical Devices ETF
2.15%
ROBO Global Healthcare Technology & Innovation ETF
1.61%
Schwab Ariel Opportunities ETF
1.6%
First Trust Health Care Alphadex Fund
1.49%
FPA Global Equity ETF
1.38%
First Eagle Global Equity ETF
1.21%
iShares Health Innovation Active ETF
1.17%
Pacer US Export Leaders ETF
1.03%
Harbor Health Care ETF
0.82%
查看更多
Parnassus Value Select ETF
占比3.94%
First Trust Indxx Medical Devices ETF
占比2.15%
ROBO Global Healthcare Technology & Innovation ETF
占比1.61%
Schwab Ariel Opportunities ETF
占比1.6%
First Trust Health Care Alphadex Fund
占比1.49%
FPA Global Equity ETF
占比1.38%
First Eagle Global Equity ETF
占比1.21%
iShares Health Innovation Active ETF
占比1.17%
Pacer US Export Leaders ETF
占比1.03%
Harbor Health Care ETF
占比0.82%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Bio Rad Laboratories Inc的前五大股东是谁?

Bio Rad Laboratories Inc 的前五大股东如下:
First Eagle Investment Management, L.L.C.持有股份:2.52M,占总股份比例:11.45%。
The Vanguard Group, Inc.持有股份:1.84M,占总股份比例:8.38%。
Alice N. Schwartz Revocable Trust持有股份:1.78M,占总股份比例:8.10%。
BlackRock Institutional Trust Company, N.A.持有股份:1.54M,占总股份比例:7.02%。
Schwartz (Norman D)持有股份:447.98K,占总股份比例:2.04%。

Bio Rad Laboratories Inc的前三大股东类型是什么?

Bio Rad Laboratories Inc 的前三大股东类型分别是:
First Eagle Investment Management, L.L.C.
The Vanguard Group, Inc.
Alice N. Schwartz Revocable Trust

有多少机构持有Bio Rad Laboratories Inc(BIO)的股份?

截至2025Q4,共有1040家机构持有Bio Rad Laboratories Inc的股份,合计持有的股份价值约为20.58M,占公司总股份的101.60%。与2025Q3相比,机构持股有所增加,增幅为-1.58%。

哪个业务部门对Bio Rad Laboratories Inc的收入贡献最大?

在FY2025Q2,--业务部门对Bio Rad Laboratories Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI